Idenix Pharmaceuticals (IDIX)

[surf1944]

8:01AM Idenix Pharma reports favorable resistance profile for IDX719, a potent, pan-genotypic HCV NS5A inhibitor, at EASL Meeting (IDIX) 3.95 : Co reported detailed resistance data from in vitro studies and from a three-day monotherapy clinical trial of IDX719, the co's once-daily, potent, pan-genotypic NS5A inhibitor for the treatment of hepatitis C virus (HCV) infection. These data are being presented on Saturday, April 27, in a poster session at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL), which is being held April 24 - 28, 2013 in Amsterdam, The Netherlands. Data from the three-day proof-of-concept study demonstrated that IDX719 was well-tolerated at daily doses up to 100 mg and showed potent antiviral activity across HCV genotypes 1-4, with mean maximal viral load reductions up to approximately 4.0 log10 IU/mL. These data were supported by earlier in vitro findings. Clinical plasma samples at baseline, at end of treatment and at one week post-treatment were sequenced for mutations in NS5A at known IDX719 resistance-associated locations.